Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children’s Oncology Group Study ANBL0531

16 Nov 2018

Abstract excerpt

PURPOSE: Infants with stage 4S neuroblastoma usually have favorable outcomes with observation or minimal chemotherapy. However, young infants with symptoms secondary to massive hepatomegaly or with unfavorable tumor biology are at high risk of death. Our aim was to improve outcomes for patients with symptomatic and/or unfavorable biology 4S neuroblastoma with a uniform treatment approach using a biology- and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer, Hypoxia, and Metabolism
Share to Neonatal Respiratory Health Research
Share to Neuroblastoma Research and Treatments

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 30444686
DOI: 10.1200/jco.18.00419

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Defining Risk Factors for Chemotherapeutic Intervention in Infants With Stage 4S Neuroblastoma: A Report From Children’s Oncology Group Study ANBL0531PMID 30444686Read ↗

Maintaining Outstanding Outcomes Using Response- and Biology-Based Therapy for Intermediate-Risk Neuroblastoma: A Report From the Children’s Oncology Group Study ANBL0531Semantic proximity Read ↗

Impact of Genomic and Clinical Factors on Outcome of Children ≥18 Months of Age with Stage 3 Neuroblastoma with Unfavorable Histology and without MYCN Amplification: A Children's Oncology Group (COG) ReportSemantic proximity Read ↗

Neuroblastoma: biology, prognosis, and treatment.Semantic proximity Read ↗

Hepatoblastoma state of the art: pathology, genetics, risk stratification, and chemotherapy.Semantic proximity Read ↗

Outcome after Reduced Chemotherapy for Intermediate-Risk NeuroblastomaSemantic proximity Read ↗

MYCN‐non‐amplified metastatic neuroblastoma with good prognosis and spontaneous regression: A molecular portrait of stage 4SSemantic proximity Read ↗

Survival of high‐risk pediatric neuroblastoma patients in a developing countrySemantic proximity Read ↗

Biology and Genetics of Human NeuroblastomasSemantic proximity Read ↗

Neuroblastoma in Infants: Long Term Survival from INES Protocols - A SIOPEN StudySemantic proximity Read ↗

Biological categories of neuroblastoma based on the international neuroblastoma pathology classification for treatment stratification.Semantic proximity Read ↗

Neuroblastoma in Infants: Long‐Term Survival From INES Protocols A SIOPEN StudySemantic proximity Read ↗

Biology of childhood hepatoblastoma and the search for novel treatmentsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.